Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis

OP0177 Randomized Comparison of Triple Dmard Therapy with Methotrexate Mono-Therapy

(2014) P. H. P. De Jong et al.   ANNALS OF THE RHEUMATIC DISEASES

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis

(2014) Sofia Ramiro et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis

(2014) Jackie L Nam et al.   ANNALS OF THE RHEUMATIC DISEASES

A comparative study of the effects of bucillamine and salazosulfapyridine in the treatment of rheumatoid arthritis

(2014) Mikio Nakajima et al.   Modern Rheumatology

Leflunomide or methotrexate? Comparison of clinical efficacy and safety in low socio-economic rheumatoid arthritis patients

(2014) Muhammad Ishaq et al.   Modern Rheumatology

Low-Dose Prednisone Inclusion in a Methotrexate-Based, Tight Control Strategy for Early Rheumatoid Arthritis

(2013) Marije F. Bakker   ANNALS OF INTERNAL MEDICINE

EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases

(2013) N Duru et al.   ANNALS OF THE RHEUMATIC DISEASES

Proposal for a new nomenclature of disease-modifying antirheumatic drugs: Table 1

(2013) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study

(2013) Désirée van der Heijde et al.   ARTHRITIS AND RHEUMATISM

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

(2013) Gerd R Burmester et al.   LANCET

Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial

(2012) P H de Jong et al.   ANNALS OF THE RHEUMATIC DISEASES

Remission induction therapy with methotrexate and prednisone in patients with early rheumatoid and undifferentiated arthritis (the IMPROVED study)

(2012) Kirsten Wevers-de Boer et al.   ANNALS OF THE RHEUMATIC DISEASES

A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: The Treatment of Early Aggressive Rheumatoid Arthritis trial

(2012) Larry W. Moreland et al.   ARTHRITIS AND RHEUMATISM

A Randomized, Double-Blind, Parallel, Single-Site Pilot Trial to Compare Two Different Starting Doses of Methotrexate in Methotrexate-Naïve Adult Patients with Rheumatoid Arthritis

(2012) Eva-Luise Hobl et al.   CLINICAL THERAPEUTICS

Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis

(2012) Roy Fleischmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

(2012) Ronald F. van Vollenhoven et al.   NEW ENGLAND JOURNAL OF MEDICINE

Are changes in bone mineral density different between groups of early rheumatoid arthritis patients treated according to a tight control strategy with or without prednisone if osteoporosis prophylaxis is applied?

(2012) M. C. van der Goes et al.   OSTEOPOROSIS INTERNATIONAL

Methodological aspects and the interpretation of clinical trial data: lessons from the TEAR trial

(2012) R. Fleischmann et al.   RHEUMATOLOGY

Low-dose oral prednisone improves clinical and ultrasonographic remission rates in early rheumatoid arthritis. Results of a 12 month open-label randomized study.

(2012) Carlomaurizio Montecucco et al.   ARTHRITIS RESEARCH & THERAPY

The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study

(2011) N. B. Klarenbeek et al.   ANNALS OF THE RHEUMATIC DISEASES

In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial

(2011) Hamed Rezaei et al.   ANNALS OF THE RHEUMATIC DISEASES

A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone

(2011) Joel M. Kremer et al.   ARTHRITIS AND RHEUMATISM

Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs

(2011) Roy Fleischmann et al.   ARTHRITIS AND RHEUMATISM

Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate

(2011) Yoshiya Tanaka et al.   ARTHRITIS CARE & RESEARCH

Early disease control by low-dose prednisone comedication may affect the quality of remission in patients with early rheumatoid arthritis

(2010) Monica Todoerti et al.   Annals of the New York Academy of Sciences

Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis

(2010) R. Knevel et al.   ANNALS OF THE RHEUMATIC DISEASES

Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis

(2010) S. L. Gorter et al.   ANNALS OF THE RHEUMATIC DISEASES

The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis

(2010) K. P. Machold et al.   ANNALS OF THE RHEUMATIC DISEASES

Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis

(2010) C. Gaujoux-Viala et al.   ANNALS OF THE RHEUMATIC DISEASES

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

(2010) J. S. Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial

(2010) Vappu Rantalaiho et al.   ARTHRITIS RESEARCH & THERAPY

Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis

(2009) L. H. D. van Tuyl et al.   ANNALS OF THE RHEUMATIC DISEASES

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo

(2009) Joel M. Kremer et al.   ARTHRITIS AND RHEUMATISM

Methotrexate therapy in rheumatoid arthritis after failure to sulphasalazine: to switch or to add?

(2009) L. G. Schipper et al.   RHEUMATOLOGY

Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis

(2008) S M van der Kooij et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial

(2008) Frank Buttgereit et al.   LANCET